R. Feenstra - Concepedia

Author

R. Feenstra

Also Known As

Feenstra, R., R W Feenstra, R. Feenstra, R. W. FEENSTRA, R.W Feenstra, R.W. Feenstra, Rebecca A. Feenstra, Roelof W. Feenstra, Roelof Willem Feenstra

Publications

246

Citations

H-Index

Concepts

All Affiliations

Radboud University Nijmegen Solvay (Netherlands)

About

R. Feenstra is an author at Radboud University Nijmegen specializing in neuroscience, medicine, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	66
2	Social Sciences	4	4	54
3	Engineering	2	2	92
4	Natural Sciences	1	1	39
5	Biochemistry	1	1	39

R. Feenstra

Publications

197

Citations

H-Index

Page 1

	Year	Citations
Interconversion of (R) and (S)-α-hydroxy esters: precursors of (S) and (R)-o-benzyl-α-hydroxylamino acid esters of high optical purity R. Feenstra, E. H. M. STOKKINGREEF, R. J. F. Nivard, Tetrahedron Engineering-O-benzyl-α-hydroxylamino Acid EstersOrganic ChemistryHigh Optical PurityChemistry	1988	53
An efficient synthesis of N-hydroxy-α-amino acid derivatives of high optical purity R. Feenstra, E. H. M. STOKKINGREEF, R. J. F. Nivard, Tetrahedron Letters DerivativesEngineeringBiochemistryNatural SciencesHigh Optical Purity	1987	39
Lens transglutaminase selects specific beta-crystallin sequences as substrate. Guy A. M. Berbers, R. Feenstra, Rémi Bos, Proceedings of the National Academy of Sciences	1984	39
DU 127090: a highly potent, atypical dopamine receptor ligand — a putative potent full spectrum antipsychotic with low EPS potential Bernard J. Van Vliet, J. Mos, J. A. M. van der Heijden, European Neuropsychopharmacology Molecular PharmacologyPsychoactive DrugPsychiatryLow Eps PotentialMedicine	2000	18
SLV313: A novel antipsychotic with additional antidepressant and anxiolytic-like actions Andrew C. McCreary, Jeffrey Glennon, T. Tuinstra, European Neuropsychopharmacology Psychoactive DrugPsychiatryMedicinePsychotropic MedicationDepression	2002	14
DU 127090: a highly potent, atypical dopamine receptor ligand — high potency but low efficacy at dopamine D2 receptors in vitro Bernard J. Van Vliet, Eric Ronken, M.Th.M. Tulp, European Neuropsychopharmacology Molecular PharmacologyFunctional SelectivityMedicineNeuropharmacologyNeuroscience	2000	12
SAR Study of 1-Aryl-4-(phenylarylmethyl)piperazines as Ligands for Both Dopamine D2 and Serotonin 5-HT1A Receptors Showing Varying Degrees of (Ant)agonism. Selection of a Potential Atypical Antipsychotic R. Feenstra, Adri van den Hoogenband, Cornelis Nicolaas Jozef Stroomer, Chemical and Pharmaceutical Bulletin Drug TargetBoth Dopamine D2PsychopharmacologyDrug Candidate Slv313Receptor Antagonism	2006	12
SLV313 is a dopamine D2 receptor antagonist and serotonin 5-HT1A receptor agonist: In vitro and in vivo neuropharmacology Jeffrey Glennon, Andrew C. McCreary, Eric Ronken, European Neuropsychopharmacology Molecular PharmacologyVivo NeuropharmacologyMedicinePsychopharmacologyNeuropharmacology	2002	10

Page 1